CARsgen Therapeutics

CARsgen is a biopharmaceutical company with operations in China and the U.S., specializing in innovative CAR T cell therapies for the treatment of hematologic malignancies and solid tumors. The company focuses on developing cutting-edge CAR T technologies to create a differentiated product pipeline aimed at making cancer curable. CARsgen serves patients with cancer, particularly those with hematologic malignancies and solid tumors, by providing advanced cell therapies. The company operates in the global biopharmaceutical market and generates revenue through the clinical trials and commercialization of its CAR T cell products. CARsgen has established a strong global presence with vertically integrated manufacturing capabilities, including the production of plasmids, lentiviral vectors, and CAR T cells. The company supports clinical trials and commercialization from its facilities in Shanghai, China, and collaborates with a diverse team of experts across borders to advance its mission. Listed on the Hong Kong Exchanges and Clearing Limited (HKEX) under stock code 2171, CARsgen continues to expand its global manufacturing capacity to meet the needs of cancer patients worldwide.

Keywords: CAR T cell therapies, hematologic malignancies, solid tumors, biopharmaceutical, innovative technologies, global presence, manufacturing capabilities, clinical trials, commercialization, cancer treatment.